Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeOSSIOOSSIO Announces U.S. Launch and First Commercial Use of the OSSIOfiber® Trimmable Fixation Nail System for Broad Utilization in Foot/Ankle and Hand/Wrist Procedures

OSSIO Announces U.S. Launch and First Commercial Use of the OSSIOfiber® Trimmable Fixation Nail System for Broad Utilization in Foot/Ankle and Hand/Wrist Procedures

July 22, 2020

OSSIO, Inc., an orthopedic fixation company, today announced the U.S. launch and first commercial use of the OSSIOfiber® Trimmable Fixation Nail System to securely fixate bone fractures, osteotomies and arthrodeses for healing, ultimately leaving the patient’s bone restored with no permanent hardware left behind.

OSSIO notes: The first commercial cases were bunion and MTP fusion procedures performed successfully by Chris Hyer, DPM, Foot and Ankle Surgeon at Polaris Surgery Center in Westerville, Ohio.

Part of the OSSIOfiber® Bone Pin Product Family, which received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) in 2019, the OSSIOfiber® Trimmable Fixation Nail System includes strong, biointegrative Trimmable Fixation Nails in 2.4mm and 4.0mm diameters packaged with corresponding sterile, disposable instrumentation.

These trimmable nails rival the performance of metal compression screws, combining the necessary strength for bone fixation with the ability to provide rapid bone in-growth, regeneration and replacement without adverse inflammation, therefore avoiding the costs, pain and complications often seen with permanent hardware. Additionally, the ability to trim the implants to any desired length enables customization to any patient anatomy and adaptability for a wide range of surgical indications including forefoot, midfoot, hindfoot and an array of hand/wrist applications.

“Having successfully utilized this new biointegrative option in my own clinical practice, it is clear that the OSSIOfiber® Trimmable Fixation Nails have real potential to replace metal compression screws and pins in numerous orthopedic procedures, with the ability to optimize bone healing while avoiding permanent implant-related post-operative complications,” said Dr. Hyer. “This novel trimmable nail system is exceptionally strong and well-designed, providing both the stability needed for solid fixation, natural healing and integration into the surrounding anatomy. The ease-of-use of the pre-sterilized, disposable instrumentation is excellent, and I like how the tapered ends of the nail allow for straightforward insertion into the bone tunnel and that it can be easily trimmed for broad procedural utility.”

OSSIO’s proprietary OSSIOfiber® technology is engineered from a high performing matrix of reinforcing mineral fibers yielding strength that is 1.5 times greater than cortical bone. The design features of the OSSIOfiber® Trimmable Fixation Nail System contribute to the ability to maintain compression, stability and fixation strength and strong pull-out strength. Additionally, the hexagonal shape of the trimmable nails resist rotation, which prevents loosening that often results in screw back-out.

Additional procedures utilizing the OSSIOfiber® Trimmable Fixation Nail System are planned across the United States in the coming weeks.

“We are pleased to bring our next biointegrative fixation system to market, providing surgeons and their patients with an alternative to metal screws and pins that deliver strength, stability and utility for multiple surgical applications – all while fully integrating into the patient’s bone and leaving nothing permanent behind,” said Brian Verrier, CEO, of the company. “Adoption of our OSSIOfiber® Bone Pin Family has been strong to date, with substantial customer utilization across the U.S. We look forward to bringing additional breakthrough technology platforms to market that utilize our proprietary OSSIOfiber® technology and deliver a new standard of care in orthopedic fixation.”

Earlier this year, the company received FDA 510(k) Clearance for its OSSIOfiber® Hammertoe Fixation System. Approximately 700 hammertoe repairs have been conducted to date utilizing the implant.

“OSSIO continues to add promising, innovative solutions that offer an alternative to metal implants to our surgical toolbox,” said Erik Carlson, MD, Hand and Upper Extremity Specialist, Active Orthopaedics PC, and Chief of Orthopaedic Surgery, St. Mary’s Hospital, Waterbury CT. “OSSIOfiber® technology has a strong performance track-record and continues to demonstrate excellent clinical outcomes in the foot and ankle space, with high surgeon and patient satisfaction across the board. I look forward to actively utilizing the customizable OSSIOfiber® Trimmable Fixation Nail System in applicable hand and wrist procedures.”

OSSIOfiber® Intelligent Bone Regeneration Technology can address many surgical applications through the manufacturing of endless implant designs, including nails, screws, anchors and plates. The company intends to pursue multiple applications in the distal extremity, trauma, sports, reconstruction, pediatrics and spine segments.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy